FoundationOne Liquid is the first and only liquid biopsy test to show prospective clinical utility in a global, registrational trial for patients with newly diagnosed, metastatic non-small cell lung cancer (NSCLC).1
- Cancer Type
- Sample Type
- Results Expected
What is FoundationOne Liquid?
FoundationOne Liquid may help inform cancer care from a simple blood draw.
This liquid biopsy test provides targeted gene and microsatellite instability-high (MSI-H) results2 that may help inform therapy selection and clinical trial options for advanced-stage cancer patients using a minimally invasive sample type. By analyzing ctDNA with our comprehensive genomic profiling approach and providing expertly curated reports, FoundationOne Liquid empowers providers to make more informed clinical decisions.
FoundationOne Liquid is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine.3
- FoundationOne Liquid is the only liquid biopsy test that has demonstrated the ability to identify patients with ALK fusions in a global prospective trial for metastatic NSCLC at similar frequencies historically published with tissue testing.6
- Includes MSI-H status and guideline-recommended genes to help inform therapy selection and identify clinical trial options for patients with solid tumors.
- Requires only two 8.5mL tubes of blood
Please see footnotes below for information on PPV and sensitivity